Active Smallcap & Microcap Investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IVDN Comprehensive Feature Article: Superior Advancement for High Energy Efficiency Insulation Drawing Rising Interest and Commercial Demand; New International Patent Application Accepted to Maximize Marketing Potential: $IVDN
Click here:
https://markets.financialcontent.com/startribune/article/getnews-2023-12-28-superior-advancement-for-high-energy-efficiency-insulation-drawing-rising-interest-and-commercial-demand-new-international-patent-application-accepted-to-maximize-marketing-potential-ivdn
$EVKRF News: Grid Battery To Begin the 2024 Exploration Program on Its Clayton Valley Lithium Project
March 13, 2024
Link to news with images:
https://marketwirenews.com/news-releases/grid-battery-to-begin-the-2024-exploration-program-o-8421939950779981.html
$EVKRF News: Grid Battery To Begin the 2024 Exploration Program on Its Clayton Valley Lithium Project
March 13, 2024
Link to news with images:
https://marketwirenews.com/news-releases/grid-battery-to-begin-the-2024-exploration-program-o-8421939950779981.html
$GTVH News: Golden Triangle Ventures Executes Purchase Agreement to Acquire Approximately 70 Prime Acres for Its Destino Ranch Project in Arizona
LAS VEGAS, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) is pleased to announce the execution of an Agreement to acquire approximately 70 acres of prime and improved land for its Destino Ranch (”Destino”) project, a flagship venture under its entertainment division. Located strategically in Arizona, this achievement marks a significant milestone for Golden Triangle Ventures. The Destino Ranch Project is planned as a multifaceted destination center set to redefine entertainment and hospitality in the region while being sustainable.
The original owner of the property has invested a significant amount of time and resources into the location and has now tapped Lavish Entertainment and its newly appointed President, Marco Moreno, to take the lead in developing the vision for Destino Ranch.
"We are thrilled to acquire this well-placed valuable piece of property with critical infrastructure in place. It will dramatically increase our speed into the market," said Moreno.
The significantly improved property currently includes perimeter fencing, graded roads, solar power systems, large permanent structures, multiple garden areas with nutrient-rich organic soil, a well, a septic system, complete irrigation systems for all the trees, security cameras, and heavy equipment for upkeep and development. These upgrades represent a substantial investment totaling nearly $6 million, which has turned this once-vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.
Situated just a few miles from a bustling freeway with easy access and well-maintained roads, Destino Ranch holds immense promise as a premier tourist destination and entertainment complex. Development plans are already underway to open the gates to the public as soon as possible. Moreno is working day and night to curate a leadership team comprised of rock stars in the entertainment and hospitality industry who will assist in the execution strategy for Destino Ranch.
Steffan Dalsgaard, CEO of Golden Triangle Ventures, stated, "This marks a significant step forward in our vision to create a one-of-a-kind destination that celebrates art, music and entertainment year-round. Our entire team is beyond confident in our ability to bring this project to life and our plan is coming closer to reality every day."
Golden Triangle Ventures is actively working to prepare a series of internal production events and will secure bookings for showcasing beginning in Q4 of 2024, further solidifying Destino Ranch's position as a premier entertainment destination. Additionally, management is excited to continue its updates with more achievements that further solidify its confidence in the development of Destino Ranch.
Destino Ranch Website: www.DestinoRanch.com
Destino Ranch Instagram: @DestinoRanch
Destino Ranch Twitter: @DestinoRanch
About Lavish Entertainment, Inc.
Lavish Entertainment, Inc. is a wholly owned subsidiary of Golden Triangle Ventures operating under its Entertainment Division. Currently conducting its business out of Las Vegas, Nevada, the Company started doing business in 2017 and was established with a vision of becoming nationally recognized in concert production. The Company currently has more than 30,000 national followers and nearly 100 team members who have helped Lavish successfully organize some of the most exciting electronic dance music concerts in Las Vegas. Lavish Entertainment strives to produce high quality and professional events that provide an immersive experience through state-of-the-art production and sound implementation.
Lavish Entertainment recently appointed Marco Antonio Moreno as its new president and chief operations officer. Mr. Moreno is the founder, senior designer and lead project manager for ABI Create, L.L.C. (“ABI”). Formed in 2015, and based out of Phoenix, Arizona, ABI is a complete-service event management and production firm offering:
-Event Organization, Management, Production and Logistics
-Site Planning and Permitting
-Construction and Contracting
-Custom Design and Fabrication
-And More
ABI Create has successfully implemented its corporate vision of delivering high-fidelity production to large-scale installations that span major music festivals, major sporting events and notable conventions across the United States. Notable collaborative work samples include projects produced for:
-NFL Super Bowl
-San Diego & New York Comic-Con
-EDC & Camp EDC and Other Insomniac Events
-Bonnaroo Music Festival
-The Waste Management Phoenix Open and Arnold Palmer Invitational
-Burning Man
More information on Mr. Moreno along with his collaborators, partners and team can be found here https://abicreate.com/ or @marco.a.moreno
ABI was a crucial team member in the production of Lavish Entertainment’s Playa Playground New Year’s event (“Playa”). Held on Dec. 31, 2021, Playa was an auspicious and grand-scale Burning-Man-style music festival staged in Downtown Las Vegas that redefined the level of event that Lavish can provide. Due to the role ABI played in the execution of Playa, the CEO of Golden Triangle Ventures, Steffan Dalsgaard handpicked Mr. Moreno to lead the new vision of Lavish and contribute to the Company’s overarching business goal of becoming an industry leading, innovative and at-the-forefront music and arts entertainment production Company.
About Golden Triangle Ventures, Inc.
Golden Triangle Ventures, Inc. or “GTV” is a multifaceted consulting Company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors along with others that provide synergistic value to these three core divisions. The Company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors this Company aims to do business in. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the Company. An amazing team of professionals support each division and continue to help the Company grow daily. Being a publicly traded Company gives the ability to provide the support needed to help each subsidiary grow into the businesses management believes they can and will become.
Golden Triangle Ventures’ business model is supported by the drive for vertical integration to cut costs and maximize margins. Management strives to acquire entities and assets that they fully understand, which maintain the prospect for long term exponential growth. The mission is to provide the necessary resources for each subsidiary to generate profit, and then allow them to leverage each other and maximize economic impact. In addition, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of different business development objectives.
The backbone of this business is truly a team of professional advisors looking to help companies with a multitude of corporate objectives. With an extensive rolodex of relationships, management can help with a dynamic range of project obstacles while maintaining a quality service for each client the Company represents. No matter what the needs are, the team involved can help facilitate many different transactions successfully for all parties involved. The network of relationships expands to industry experts that can assist with project management, product sourcing, industrial agriculture project implementation and so much more. Golden Triangle Ventures develops strategies and detailed plans that are custom-tailored to each corporate need and objective in all areas of business.
The GTV business model is focused on the following core group of interests:
Acquisitions / Assets / Holdings - The Company currently owns a unique portfolio of companies that are all being developed and supported by GTV, each holding a common goal of making a positive impact in the industry in which they operate.
Services - Services are deployed through Golden Triangle Ventures to assist all the unique opportunities within its operation. The Company also offers its services to select opportunities that could develop synergistic value within the relationship between both companies through the result of its efforts.
Investments - Management identifies high-value opportunities and provides capital investments in several companies and projects being developed. Each investment is complemented by a hands-on approach of helping to develop the overall direction and strategic plan for each opportunity.
http://www.GoldenTriangleInc.com
FORWARD-LOOKING INFORMATION
Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to give potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our Company website, www.GoldenTriangleInc.com, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our Company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our Company to review the information we post on the following U.S. social media channels:
Twitter: www.twitter.com/GTV_Inc
CONTACT INFORMATION
Golden Triangle Ventures, Inc.
3035 E Patrick Ln. #15
Las Vegas, NV 89120
info@GoldenTriangleInc.com
1-800-469-2614
Corporate Communications
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
$GTVH News: Golden Triangle Ventures Executes Purchase Agreement to Acquire Approximately 70 Prime Acres for Its Destino Ranch Project in Arizona
LAS VEGAS, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) is pleased to announce the execution of an Agreement to acquire approximately 70 acres of prime and improved land for its Destino Ranch (”Destino”) project, a flagship venture under its entertainment division. Located strategically in Arizona, this achievement marks a significant milestone for Golden Triangle Ventures. The Destino Ranch Project is planned as a multifaceted destination center set to redefine entertainment and hospitality in the region while being sustainable.
The original owner of the property has invested a significant amount of time and resources into the location and has now tapped Lavish Entertainment and its newly appointed President, Marco Moreno, to take the lead in developing the vision for Destino Ranch.
"We are thrilled to acquire this well-placed valuable piece of property with critical infrastructure in place. It will dramatically increase our speed into the market," said Moreno.
The significantly improved property currently includes perimeter fencing, graded roads, solar power systems, large permanent structures, multiple garden areas with nutrient-rich organic soil, a well, a septic system, complete irrigation systems for all the trees, security cameras, and heavy equipment for upkeep and development. These upgrades represent a substantial investment totaling nearly $6 million, which has turned this once-vacant land into a beautiful oasis that provides the initial infrastructure needed to begin the development of Destino Ranch.
Situated just a few miles from a bustling freeway with easy access and well-maintained roads, Destino Ranch holds immense promise as a premier tourist destination and entertainment complex. Development plans are already underway to open the gates to the public as soon as possible. Moreno is working day and night to curate a leadership team comprised of rock stars in the entertainment and hospitality industry who will assist in the execution strategy for Destino Ranch.
Steffan Dalsgaard, CEO of Golden Triangle Ventures, stated, "This marks a significant step forward in our vision to create a one-of-a-kind destination that celebrates art, music and entertainment year-round. Our entire team is beyond confident in our ability to bring this project to life and our plan is coming closer to reality every day."
Golden Triangle Ventures is actively working to prepare a series of internal production events and will secure bookings for showcasing beginning in Q4 of 2024, further solidifying Destino Ranch's position as a premier entertainment destination. Additionally, management is excited to continue its updates with more achievements that further solidify its confidence in the development of Destino Ranch.
Destino Ranch Website: www.DestinoRanch.com
Destino Ranch Instagram: @DestinoRanch
Destino Ranch Twitter: @DestinoRanch
About Lavish Entertainment, Inc.
Lavish Entertainment, Inc. is a wholly owned subsidiary of Golden Triangle Ventures operating under its Entertainment Division. Currently conducting its business out of Las Vegas, Nevada, the Company started doing business in 2017 and was established with a vision of becoming nationally recognized in concert production. The Company currently has more than 30,000 national followers and nearly 100 team members who have helped Lavish successfully organize some of the most exciting electronic dance music concerts in Las Vegas. Lavish Entertainment strives to produce high quality and professional events that provide an immersive experience through state-of-the-art production and sound implementation.
Lavish Entertainment recently appointed Marco Antonio Moreno as its new president and chief operations officer. Mr. Moreno is the founder, senior designer and lead project manager for ABI Create, L.L.C. (“ABI”). Formed in 2015, and based out of Phoenix, Arizona, ABI is a complete-service event management and production firm offering:
-Event Organization, Management, Production and Logistics
-Site Planning and Permitting
-Construction and Contracting
-Custom Design and Fabrication
-And More
ABI Create has successfully implemented its corporate vision of delivering high-fidelity production to large-scale installations that span major music festivals, major sporting events and notable conventions across the United States. Notable collaborative work samples include projects produced for:
-NFL Super Bowl
-San Diego & New York Comic-Con
-EDC & Camp EDC and Other Insomniac Events
-Bonnaroo Music Festival
-The Waste Management Phoenix Open and Arnold Palmer Invitational
-Burning Man
More information on Mr. Moreno along with his collaborators, partners and team can be found here https://abicreate.com/ or @marco.a.moreno
ABI was a crucial team member in the production of Lavish Entertainment’s Playa Playground New Year’s event (“Playa”). Held on Dec. 31, 2021, Playa was an auspicious and grand-scale Burning-Man-style music festival staged in Downtown Las Vegas that redefined the level of event that Lavish can provide. Due to the role ABI played in the execution of Playa, the CEO of Golden Triangle Ventures, Steffan Dalsgaard handpicked Mr. Moreno to lead the new vision of Lavish and contribute to the Company’s overarching business goal of becoming an industry leading, innovative and at-the-forefront music and arts entertainment production Company.
About Golden Triangle Ventures, Inc.
Golden Triangle Ventures, Inc. or “GTV” is a multifaceted consulting Company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors along with others that provide synergistic value to these three core divisions. The Company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors this Company aims to do business in. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the Company. An amazing team of professionals support each division and continue to help the Company grow daily. Being a publicly traded Company gives the ability to provide the support needed to help each subsidiary grow into the businesses management believes they can and will become.
Golden Triangle Ventures’ business model is supported by the drive for vertical integration to cut costs and maximize margins. Management strives to acquire entities and assets that they fully understand, which maintain the prospect for long term exponential growth. The mission is to provide the necessary resources for each subsidiary to generate profit, and then allow them to leverage each other and maximize economic impact. In addition, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of different business development objectives.
The backbone of this business is truly a team of professional advisors looking to help companies with a multitude of corporate objectives. With an extensive rolodex of relationships, management can help with a dynamic range of project obstacles while maintaining a quality service for each client the Company represents. No matter what the needs are, the team involved can help facilitate many different transactions successfully for all parties involved. The network of relationships expands to industry experts that can assist with project management, product sourcing, industrial agriculture project implementation and so much more. Golden Triangle Ventures develops strategies and detailed plans that are custom-tailored to each corporate need and objective in all areas of business.
The GTV business model is focused on the following core group of interests:
Acquisitions / Assets / Holdings - The Company currently owns a unique portfolio of companies that are all being developed and supported by GTV, each holding a common goal of making a positive impact in the industry in which they operate.
Services - Services are deployed through Golden Triangle Ventures to assist all the unique opportunities within its operation. The Company also offers its services to select opportunities that could develop synergistic value within the relationship between both companies through the result of its efforts.
Investments - Management identifies high-value opportunities and provides capital investments in several companies and projects being developed. Each investment is complemented by a hands-on approach of helping to develop the overall direction and strategic plan for each opportunity.
http://www.GoldenTriangleInc.com
FORWARD-LOOKING INFORMATION
Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to give potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our Company website, www.GoldenTriangleInc.com, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our Company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our Company to review the information we post on the following U.S. social media channels:
Twitter: http://www.twitter.com/GTV_Inc
CONTACT INFORMATION
Golden Triangle Ventures, Inc.
3035 E Patrick Ln. #15
Las Vegas, NV 89120
info@GoldenTriangleInc.com
1-800-469-2614
Corporate Communications
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
$GDHG News: Golden Heaven Group Holdings Ltd. Announces Guest Visits Increased During the 2024 Chinese Spring Festival Holiday
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-130000542.html
$IVDN has rising sales, new customers, new distributors, patent protection, no debt, insider buying, a small share structure with a very low float of only 16 million shares out, all legal issues resolved in the company's favor and, of course, the highest performing House Wrap insulation on the market with its unique evacuated cell structure delivering an R-6 value that no competitor can mach.
All of this has come together as a result of management's diligent work over the past several years and has brought the company to its strongest position ever for 2024 and beyond. Everything is well detailed in the official company news we have been seeing. Per the latest financial filing, the company has just reported a 35% increase is sales revenue for its fiscal year ended on Oct. 31st, demonstrating that they are on a positive growth curve now.
World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640
LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html
Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html
Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html
Innovative Designs, Inc. Receives $100,000 Direct Private Investment from Board Member Mr. Robert K. Adams
June 5, 2023
https://www.globenewswire.com/news-release/2023/06/05/2682134/0/en/Innovative-Designs-Inc-Receives-100-000-Direct-Private-Investment-from-Board-Member-Mr-Robert-K-Adams.html
Innovative Designs, Inc. Receives Significant New Orders for Its Unmatched Insultex House Wrap from Two Repeat Customers
June 1, 2023
https://www.globenewswire.com/news-release/2023/06/01/2680753/0/en/Innovative-Designs-Inc-Receives-Significant-New-Orders-for-Its-Unmatched-Insultex-House-Wrap-from-Two-Repeat-Customers.html
Innovative Designs Receives Patent for Propriety Process With Low Density Foam
April 20, 2023
https://www.globenewswire.com/news-release/2023/04/20/2651420/0/en/Innovative-Designs-Receives-Patent-for-Propriety-Process-With-Low-Density-Foam.html
$AVRW looks very undervalued and oversold right now, especially with the high prospects that company has in play to deliver a record sales growth year in 20204. This was clearly laid out in the latest official company news below.
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
February 13, 2024
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
Yes, AVRW looks very undervalued and oversold right now, especially with the high prospects that the company has in play to deliver a record sales growth year in 20204. This was clearly laid out in the latest official company news below. This is valuable information for real investors to review as we await more developments.
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
February 13, 2024
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities
The Company is contemplating a reverse split, if needed to maintain NASDAQ listing compliance, to be accompanied by change in corporate name and CUSIP number
Company has retained former SEC enforcement leadership to notify leading brokerages of the need to close all naked short positions in the Company's securities and to prevent future accumulation of naked short positions in the Company's new security
RADNOR, Pa., March 12, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company" today initiated actions to combat short sellers in the Company's stock.
The Company announced a proposal to simultaneously change the CUSIP under which the Company's shares are traded, together with changing the name of the Company to NRx Therapeutics, Inc. The Company plans to accompany these actions with a required exchange of the underlying stock certificates. This certificate change is expected to be seamless for those investors holding NRXP shares in electronic form and similarly for investors who may have established short positions in NRXP by borrowing the underlying shares from a registered shareholder. Any party holding a short position in the Company's shares who has not complied with the legal requirement to borrow the underlying shares of stock (i.e. "a naked short" may be unable to exchange that position for a position in the new security.
The Company is working with attorneys who formerly served in leadership positions at the SEC Division of Enforcement to correspond with corporate counsel and compliance heads at leading brokerages to emphasize the current legal prohibitions against naked short sales. As identified in previous announcements, the Company was advised by ShareIntel in September 2023 that substantial naked short positions in the Company's securities had been identified at major brokerage firms.
"We believe it is in the best interests of our shareholders to have fully-compliant trading in the markets," said Janet Rehnquist, Esq., who chairs the Company's Compliance Committee. "As we focus on the development of potentially life-saving drugs to combat suicidal depression, PTSD, and Chronic Pain, it is critical that we take all steps possible to maximize the value of those who have invested in our Company and provided the resources to address these critical unmet medical needs."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-initiates-strategy-to-combat-short-sales-302086668.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities
The Company is contemplating a reverse split, if needed to maintain NASDAQ listing compliance, to be accompanied by change in corporate name and CUSIP number
Company has retained former SEC enforcement leadership to notify leading brokerages of the need to close all naked short positions in the Company's securities and to prevent future accumulation of naked short positions in the Company's new security
RADNOR, Pa., March 12, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company" today initiated actions to combat short sellers in the Company's stock.
The Company announced a proposal to simultaneously change the CUSIP under which the Company's shares are traded, together with changing the name of the Company to NRx Therapeutics, Inc. The Company plans to accompany these actions with a required exchange of the underlying stock certificates. This certificate change is expected to be seamless for those investors holding NRXP shares in electronic form and similarly for investors who may have established short positions in NRXP by borrowing the underlying shares from a registered shareholder. Any party holding a short position in the Company's shares who has not complied with the legal requirement to borrow the underlying shares of stock (i.e. "a naked short" may be unable to exchange that position for a position in the new security.
The Company is working with attorneys who formerly served in leadership positions at the SEC Division of Enforcement to correspond with corporate counsel and compliance heads at leading brokerages to emphasize the current legal prohibitions against naked short sales. As identified in previous announcements, the Company was advised by ShareIntel in September 2023 that substantial naked short positions in the Company's securities had been identified at major brokerage firms.
"We believe it is in the best interests of our shareholders to have fully-compliant trading in the markets," said Janet Rehnquist, Esq., who chairs the Company's Compliance Committee. "As we focus on the development of potentially life-saving drugs to combat suicidal depression, PTSD, and Chronic Pain, it is critical that we take all steps possible to maximize the value of those who have invested in our Company and provided the resources to address these critical unmet medical needs."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-initiates-strategy-to-combat-short-sales-302086668.html
SOURCE NRx Pharmaceuticals, Inc.
$EVKRF News: Grid Battery Metals Files NI 43-101 Technical Report on its Clayton Valley Lithium Project in Nevada
March 6, 2024
Link: https://finance.yahoo.com/news/grid-battery-metals-files-ni-123000689.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$GDHG News: Golden Heaven Group Holdings Ltd. Announces Guest Visits Increased During the 2024 Chinese Spring Festival Holiday
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-130000542.html
$GDHG News: Golden Heaven Group Holdings Ltd. Announces Guest Visits Increased During the 2024 Chinese Spring Festival Holiday
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-130000542.html
$AVRW is due to report its year end financial results by March 31st which should demonstrate that the company is on a positive revenue growth curve as all the official news has indicated. From the most recent update issued on February 13th we can expect good news for all of 2024...
-----------------------------------------------------------------------------------------------------------
Overall, Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
AVRW is due to report its year end financial results by March 31st which should demonstrate that the company is on a positive revenue growth curve as all the official news has indicated. From the most recent update issued on February 13th we can expect good news for all of 2024...
-----------------------------------------------------------------------------------------------------------
Overall, Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Sincerely,
Nancy Duitch, CEO
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$IVDN (16 million float) has rising sales, new customers, new distributors, patent protection, no debt, insider buying, a small share structure with a very low float of only 16 million shares out, all legal issues resolved in the company's favor and, of course, the highest performing House Wrap insulation on the market with its unique evacuated cell structure delivering an R-6 value that no competitor can mach.
All of this has come together as a result of management's diligent work over the past several years and has brought the company to its strongest position ever for 2024 and beyond. Everything is well detailed in the official company news we have been seeing. Per the latest financial filing, the company has just reported a 35% increase is sales revenue for its fiscal year ended on Oct. 31st, demonstrating that they are on a positive growth curve now.
World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640
LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html
Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html
Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html
Innovative Designs, Inc. Receives $100,000 Direct Private Investment from Board Member Mr. Robert K. Adams
June 5, 2023
https://www.globenewswire.com/news-release/2023/06/05/2682134/0/en/Innovative-Designs-Inc-Receives-100-000-Direct-Private-Investment-from-Board-Member-Mr-Robert-K-Adams.html
Innovative Designs, Inc. Receives Significant New Orders for Its Unmatched Insultex House Wrap from Two Repeat Customers
June 1, 2023
https://www.globenewswire.com/news-release/2023/06/01/2680753/0/en/Innovative-Designs-Inc-Receives-Significant-New-Orders-for-Its-Unmatched-Insultex-House-Wrap-from-Two-Repeat-Customers.html
Innovative Designs Receives Patent for Propriety Process With Low Density Foam
April 20, 2023
https://www.globenewswire.com/news-release/2023/04/20/2651420/0/en/Innovative-Designs-Receives-Patent-for-Propriety-Process-With-Low-Density-Foam.html
$IVDN Insultex House Wrap offers its superior R-6 Rating that beats every competitive product! The company has posted its independent laboratory testing data, which is present on the company website: https://insultexhousewrap.com/testing-info/ #construction #R6rating #insultexhousewrap
$IVDN Insultex House Wrap offers its superior R-6 Rating that beats every competitive product! The company has posted its independent laboratory testing data, which is present on the company website:https://t.co/PGqKLwnznV#construction #R6rating #insultexhousewrap #lindus pic.twitter.com/yYPZyXFtUs
— 🔥🔥🌐UltimateTraderX🌐🔥🔥 (@JediJazz22) March 5, 2024
$NRXP: NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
Company to receive first allocation of ketamine for sale by month end
Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies
NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply
Important step toward goal of providing full suite of supply options, to ultimately include an FDA approved, and widely reimbursed, solution for patients and clinics, subject to board approval
RADNOR, Pa., March 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") and its wholly owned subsidiary HOPE Therapeutics, clinical-stage biopharmaceutical companies, today announced completion of a Memorandum of Understanding with Conversio Health, a national 503a pharmacy, and a strong, ongoing partnership with Nephron Pharmaceuticals, a manufacturer of Ketamine and 503b pharmacy to provide IV Ketamine to patients and clinics across the country, subject to board approval. These are important steps to providing a full suite of ketamine options for customers across the country, and preparation for potential approval of HTX-100 by regulatory authorities worldwide.
(PRNewsfoto/NRx Pharmaceuticals)
(PRNewsfoto/NRx Pharmaceuticals)
The Company has further entered into a business relationship with an organization that currently serves the business needs of more than 100 ketamine clinics nationwide. The Company has been given a target delivery date prior to the end of this month (March 2024) for initial stock of ketamine for sale to licensed end users. Sales are planned to commence once technical and logistical elements are finalized. Details for ordering will be available on our website as soon as they are available. www.hopetherapeutics.com
In contrast to NRx Pharmaceuticals, which is structured as a Biotechnology research and development company, HOPE Therapeutics is structured as a Specialty Pharmaceutical company that aims to supply a variety of therapeutic products to clinics that are treating suicidal depression and PTSD, including both traditional and digital therapeutics.
"We are pleased to be working with two outstanding organizations in Conversio Health and Nephron Pharmaceuticals to provide this important medication to a market in need of a consistent supply of high-quality, FDA- and DEA- compliant IV ketamine," said Matthew Duffy Chief Business Officer of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics. "Importantly, these efforts will provide a strong foundation for expanding our product offering with our planed filing a New Drug Application with the FDA in the coming months, and the potential launch of HTX-100 in early 2025." The NDA filing currently awaits completion of an additional three months of product stability.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through HOPE Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-completes-memorandum-of-understanding-and-collaborations-with-distribution-partners-for-htx-100-iv-ketamine-302085271.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP: NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
Company to receive first allocation of ketamine for sale by month end
Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies
NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply
Important step toward goal of providing full suite of supply options, to ultimately include an FDA approved, and widely reimbursed, solution for patients and clinics, subject to board approval
RADNOR, Pa., March 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") and its wholly owned subsidiary HOPE Therapeutics, clinical-stage biopharmaceutical companies, today announced completion of a Memorandum of Understanding with Conversio Health, a national 503a pharmacy, and a strong, ongoing partnership with Nephron Pharmaceuticals, a manufacturer of Ketamine and 503b pharmacy to provide IV Ketamine to patients and clinics across the country, subject to board approval. These are important steps to providing a full suite of ketamine options for customers across the country, and preparation for potential approval of HTX-100 by regulatory authorities worldwide.
(PRNewsfoto/NRx Pharmaceuticals)
(PRNewsfoto/NRx Pharmaceuticals)
The Company has further entered into a business relationship with an organization that currently serves the business needs of more than 100 ketamine clinics nationwide. The Company has been given a target delivery date prior to the end of this month (March 2024) for initial stock of ketamine for sale to licensed end users. Sales are planned to commence once technical and logistical elements are finalized. Details for ordering will be available on our website as soon as they are available. www.hopetherapeutics.com
In contrast to NRx Pharmaceuticals, which is structured as a Biotechnology research and development company, HOPE Therapeutics is structured as a Specialty Pharmaceutical company that aims to supply a variety of therapeutic products to clinics that are treating suicidal depression and PTSD, including both traditional and digital therapeutics.
"We are pleased to be working with two outstanding organizations in Conversio Health and Nephron Pharmaceuticals to provide this important medication to a market in need of a consistent supply of high-quality, FDA- and DEA- compliant IV ketamine," said Matthew Duffy Chief Business Officer of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics. "Importantly, these efforts will provide a strong foundation for expanding our product offering with our planed filing a New Drug Application with the FDA in the coming months, and the potential launch of HTX-100 in early 2025." The NDA filing currently awaits completion of an additional three months of product stability.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through HOPE Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-completes-memorandum-of-understanding-and-collaborations-with-distribution-partners-for-htx-100-iv-ketamine-302085271.html
SOURCE NRx Pharmaceuticals, Inc.
IVDN has rising sales, new customers, new distributors, patent protection, no debt, insider buying, a small share structure with a very low float of only 16 million shares out, all legal issues resolved in the company's favor and, of course, the highest performing House Wrap insulation on the market with its unique evacuated cell structure delivering an R-6 value that no competitor can mach.
All of this has come together as a result of management's diligent work over the past several years and has brought the company to its strongest position ever for 2024 and beyond. Everything is well detailed in the official company news we have been seeing. Per the latest financial filing, the company has just reported a 35% increase is sales revenue for its fiscal year ended on Oct. 31st, demonstrating that they are on a positive growth curve now.
Those who read and appreciate the high value and payoff potential here can profit greatly with a little patience. Those who fail to see the big picture developing will likely be left behind.
World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640
LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html
Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html
Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html
Innovative Designs, Inc. Receives $100,000 Direct Private Investment from Board Member Mr. Robert K. Adams
June 5, 2023
https://www.globenewswire.com/news-release/2023/06/05/2682134/0/en/Innovative-Designs-Inc-Receives-100-000-Direct-Private-Investment-from-Board-Member-Mr-Robert-K-Adams.html
Innovative Designs, Inc. Receives Significant New Orders for Its Unmatched Insultex House Wrap from Two Repeat Customers
June 1, 2023
https://www.globenewswire.com/news-release/2023/06/01/2680753/0/en/Innovative-Designs-Inc-Receives-Significant-New-Orders-for-Its-Unmatched-Insultex-House-Wrap-from-Two-Repeat-Customers.html
Innovative Designs Receives Patent for Propriety Process With Low Density Foam
April 20, 2023
https://www.globenewswire.com/news-release/2023/04/20/2651420/0/en/Innovative-Designs-Receives-Patent-for-Propriety-Process-With-Low-Density-Foam.html
Two additional postings from $GTVH CEO Steffan Dalsgaard today addressing the share structure issue and company business growth projections ... I understand the concerns voiced by our shareholders regarding stock dilution. We're fully engaged in addressing these concerns while tackling the myriad challenges we face, all with a firm commitment to executing the strongest possible plan for the benefit of our company. $GTVH Furthermore, our team is committed to a clear trajectory, prioritizing our Entertainment and Health division. I have every confidence that our upcoming projects will not only address our past debt commitments effectively but also generate considerable value for our shareholders
Steff D@steffD415·I understand the concerns voiced by our shareholders regarding stock dilution. We're fully engaged in addressing these concerns while tackling the myriad challenges we face, all with a firm commitment to executing the strongest possible plan for the benefit of our company. $GTVH
;
Steff D@steffD415 Furthermore, our team is committed to a clear trajectory, prioritizing our Entertainment and Health division. I have every confidence that our upcoming projects will not only address our past debt commitments effectively but also generate considerable value for our shareholders
More from $GTVH CEO Steffan Dalsgaard: Steff D@steffD415 Our physical assets owned by $GTVH are valued far above our entire market cap. Destino Ranch will become something so epic and when the world sees what we are building within our Health division, it’s game over for all that have ever doubted us. Our physical assets owned by $GTVH are valued far above our entire market cap. Destino Ranch will become something so epic and when the world sees what we are building within our Health division, it’s game over for all that have ever doubted us.
Long-time IVDN customer and very successful home remodeler Lindus Construction strongly endorses the Insultex House Wrap product. In fact, Lindus has dedicated an entire section of their own company website to introduce their customers to the advantages of IVDN Insultex. They are quite impressed and fully satisfied with its performance which far exceeds all competitive products on the market.
See the Lindus company website with their commentary here: https://lindusconstruction.com/blog/insultex-house-wrap-future-home-weatherization/.
IVDN is presently selling its Insultex insulation products to multiple existing and new customers who are fully satisfied with its superior R-6 Rated energy efficiency performance. The current ASTM testing certification data is available on the dedicated Insultex House Wrap website at: https://insultexhousewrap.com/testing-info/
Dickmo, check out my previous post here with another new posting from IVDN management. They are clearly on top of this new issue in 2024 with the changing building codes that directly favor the advantages which Insultex provides (and many competitive products do not). The new requirement for continuous insulation and other new codes is becoming so important that there are now educational training courses being offered for construction professionals across the US.
$IVDN: Our patented Insultex House Wrap (TM) with an unmatched R-6 Rating is an ideal solution to meet new building codes requiring continuous insulation and higher thermal performance. A unique evacuated cell design makes this possible. Visit: http://insultexhousewrap.com #Insulation
$IVDN: Our patented Insultex House Wrap (TM) with an unmatched R-6 Rating is an ideal solution to meet new building codes requiring continuous insulation and higher thermal performance. A unique evacuated cell design makes this possible. Visit: https://t.co/7DxiK13HDH #Insulation https://t.co/xbs34YQZEw
— Innovative Designs, Inc (Stock: $IVDN) (@riccelli_joseph) March 7, 2024
The crisis situations we see in the news everyday now certainly illustrate the need for more security response products as the Lamperd Less Lethal line offers. This being the big election year, the news is likely only going to get more intense. Lamperd is licensed and set up to supply police, military and other government agencies in many countries around the world, including the USA, of course.
-----------------------------------------------------------------------------------------------------------------------------------
About Lamperd Less Lethal:
Lamperd Less Lethal, Inc. (LLLI) is a developer, manufacturer and international sales company for advanced less lethal weapons, ammunition and other security products marketed to police, correctional, military and private security forces. The company manufactures and sells over 300 different products including small & large caliber projectile guns, flash-bang devices, pepper spray devices, 12 Gauge, 37mm & 40mm launching systems and a variety of different riot shields. Lamperd also offers advisory services and hands-on training classes run by highly accredited instructors.
For more information visit: http://www.lamperdlesslethal.com
$GTVH Update from CEO Steffan Dalsgaard: Steff D@steffD415 We are working to share a lot more information on progress and developments within Destino Ranch and the other exciting projects within $GTVH - I think it would be fun to do a spaces event with Marco and I to hear what’s been cooking
We are working to share a lot more information on progress and developments within Destino Ranch and the other exciting projects within $GTVH - I think it would be fun to do a spaces event with Marco and I to hear what’s been cooking 👀
— Steffan Dalsgaard (@SteffD415) March 2, 2024
$GDHG News: Golden Heaven Group Holdings Ltd. Announces Guest Visits Increased During the 2024 Chinese Spring Festival Holiday
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-130000542.html
$NRXP News: NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression
The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter
Study maintained 95% concordance rate between study sites and central raters on primary endpoint. No unexpected Serious Adverse Events were reported.
Positive data and FDA comment would trigger the next $4 million milestone payment from partners Alvogen and Lotus and their assumption of development costs; agreement provides for up to $329 million in milestone payments and a royalty on Net Sales in the mid-teens
RADNOR, Pa., March 4, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the 74th and last evaluable patient has completed their day 42 visit in its Phase 2b/3 study of NRX-101, the Company's patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. The database is being cleaned, finalized, and locked; statistical analysis will then be performed, with top-line data to follow shortly thereafter. As previously disclosed, positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.
NRX-101 has been awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression. It is the only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression, a lethal disease that claims the lives of one in five who live with it.
"This is the first clinical trial, to the company's knowledge, conducted among patients with suicidal bipolar depression in the outpatient setting. Our previous trial measured the ability of NRX-101 to maintain the anti-depressant and anti-suicidal effect of ketamine administered in the hospital setting. These patients, whose clinical need is urgent and extraordinary have routinely been excluded from the clinical trials of all previously-known anti-depressant drugs. said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. Although there were patients whose depression worsened and required hospitalization (we don't yet know whether they were on NRX-101 or comparator), patient safety was maintained, and no trial participant suffered a serious unexpected adverse outcome. Our thanks go out to our investigators, clinics, partners and, most importantly, our amazing patients and their families for seeing this study through to this important milestone," "
The Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of 94%, well above the industry standard that is normally seen in CNS trials.
Top-line results are expected around the end of this quarter.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL51263&sd=2024-03-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaq-nrxp-announces-last-patient-last-visit-in-its-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302078041.html
SOURCE NRx Pharmaceuticals, Inc.
$AVRW: Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$AVRW: Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$EVKRF News: Grid Battery Metals Files NI 43-101 Technical Report on its Clayton Valley Lithium Project in Nevada
March 6, 2024
Link: https://finance.yahoo.com/news/grid-battery-metals-files-ni-123000689.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$EVKRF News: Grid Battery Metals Files NI 43-101 Technical Report on its Clayton Valley Lithium Project in Nevada
March 6, 2024
Link: https://finance.yahoo.com/news/grid-battery-metals-files-ni-123000689.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$CETX News: Cemtrex Announces Beta Release of Pioneering AI Gun Detection Feature
Disruptive Artificial Intelligence (AI) Gun Detection Feature to Launch in the Second Calendar Quarter of 2024, Marking a Significant Milestone Achievement for Detecting Armed Persons in Surveillance Footage
Hauppauge, NY, March 06, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, today announced that its subsidiary, Vicon, is expected to commence the beta release of its innovative Artificial Intelligence (AI) gun detection feature in the second calendar quarter of 2024, marking a significant milestone in public safety and security technology. This groundbreaking feature is designed to function on edge devices, offering a low-cost, high-efficiency solution for detecting armed persons in surveillance footage and enhancing the capabilities of video management systems to initiate specific responses upon detection.
The introduction of this AI feature, with full commercialization planned for the second half of 2024, is part of Vicon’s commitment to developing cutting-edge solutions that meet the dynamic needs of our customers. This commercialization strategy allows for gathering real-world insights and refining the technology based on feedback from live environments, ensuring the delivery of a superior product experience. Current solutions on the market are generally server-based which are extremely cost prohibitive and difficult to deploy, whereas Vicon’s approach for an edge-based solution, offers a more effective alternative.
Vicon, in collaboration with its technology partners, is developing this feature to provide real-time alerts and facilitate rapid response, thereby playing a crucial role in enhancing security measures and potentially preventing violent incidents before they occur. The value of integrating gun detection technology into video surveillance systems offers significant advancements in the ability of organizations to protect their premises and the people within them, providing peace of mind in increasingly uncertain times.
"Our goal is not only to innovate but to make a meaningful contribution to public safety," said Saagar Govil, CEO of Cemtrex. "The early adoption and feedback through our beta release are vital in shaping a solution that truly meets societal needs. By making advanced gun detection technology accessible and affordable, we aim to equip organizations with the tools they need to enhance their security protocols and respond more effectively to potential threats."
Gun violence remains a pressing issue in the United States, with provisional data for 2022 from the Centers for Disease Control and Prevention highlighting the urgent need for innovative solutions:
Over 48,000 firearm-related deaths, including nearly 20,000 homicides, were recorded in the U.S.
An average, 132 Americans died from a firearm-related injury each day, with hundreds more shot and injured.
Guns remained the leading cause of death for children and teens, climbing 87% in the last decade.
Recent years have seen a stark increase in school shootings, with 2021, 2022 and 2023 all setting records since at least 2008. There were at least 82 incidents in 2023, but 2022 was one of the deadliest years, with 46 fatalities, according to CNN.
Vicon's AI gun detection technology aims to contribute significantly to efforts to reduce gun violence and its devastating impact on communities across the nation. The Company sees the market opportunity for this feature to be vast, ranging from schools, hospitals, government buildings, retail, to religious institutions.
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit www.ais-york.com
For more information visit www.cemtrex.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the closing of the offering, gross proceeds from the offering, our new product offerings, expected use of proceeds, or any proposed fundraising activities. These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.
https://www.globenewswire.com/newsroom/ti?nf=OTA1OTAyMiM2MTIzNTA1IzIwNDk3MDg=
https://ml.globenewswire.com/media/YmFhNDM0Y2ItNmNiNS00MmQ5LThkNDgtNGYyMDA2ZDBlNWU4LTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.
$CETX News: Cemtrex Announces Beta Release of Pioneering AI Gun Detection Feature
Disruptive Artificial Intelligence (AI) Gun Detection Feature to Launch in the Second Calendar Quarter of 2024, Marking a Significant Milestone Achievement for Detecting Armed Persons in Surveillance Footage
Hauppauge, NY, March 06, 2024 (GLOBE NEWSWIRE) -- - Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, today announced that its subsidiary, Vicon, is expected to commence the beta release of its innovative Artificial Intelligence (AI) gun detection feature in the second calendar quarter of 2024, marking a significant milestone in public safety and security technology. This groundbreaking feature is designed to function on edge devices, offering a low-cost, high-efficiency solution for detecting armed persons in surveillance footage and enhancing the capabilities of video management systems to initiate specific responses upon detection.
The introduction of this AI feature, with full commercialization planned for the second half of 2024, is part of Vicon’s commitment to developing cutting-edge solutions that meet the dynamic needs of our customers. This commercialization strategy allows for gathering real-world insights and refining the technology based on feedback from live environments, ensuring the delivery of a superior product experience. Current solutions on the market are generally server-based which are extremely cost prohibitive and difficult to deploy, whereas Vicon’s approach for an edge-based solution, offers a more effective alternative.
Vicon, in collaboration with its technology partners, is developing this feature to provide real-time alerts and facilitate rapid response, thereby playing a crucial role in enhancing security measures and potentially preventing violent incidents before they occur. The value of integrating gun detection technology into video surveillance systems offers significant advancements in the ability of organizations to protect their premises and the people within them, providing peace of mind in increasingly uncertain times.
"Our goal is not only to innovate but to make a meaningful contribution to public safety," said Saagar Govil, CEO of Cemtrex. "The early adoption and feedback through our beta release are vital in shaping a solution that truly meets societal needs. By making advanced gun detection technology accessible and affordable, we aim to equip organizations with the tools they need to enhance their security protocols and respond more effectively to potential threats."
Gun violence remains a pressing issue in the United States, with provisional data for 2022 from the Centers for Disease Control and Prevention highlighting the urgent need for innovative solutions:
Over 48,000 firearm-related deaths, including nearly 20,000 homicides, were recorded in the U.S.
An average, 132 Americans died from a firearm-related injury each day, with hundreds more shot and injured.
Guns remained the leading cause of death for children and teens, climbing 87% in the last decade.
Recent years have seen a stark increase in school shootings, with 2021, 2022 and 2023 all setting records since at least 2008. There were at least 82 incidents in 2023, but 2022 was one of the deadliest years, with 46 fatalities, according to CNN.
Vicon's AI gun detection technology aims to contribute significantly to efforts to reduce gun violence and its devastating impact on communities across the nation. The Company sees the market opportunity for this feature to be vast, ranging from schools, hospitals, government buildings, retail, to religious institutions.
About Cemtrex
Cemtrex Inc. (CETX) is a company that owns two operating subsidiaries: Vicon Industries Inc and Advanced Industrial Services Inc.
Vicon Industries, a subsidiary of Cemtrex Inc., is a global leader in advanced security and surveillance technology to safeguard businesses, schools, municipalities, hospitals and cities. Since 1967, Vicon delivers mission-critical security surveillance systems, specializing in engineering complete security solutions that simplify deployment, operation and ongoing maintenance. Vicon provides security solutions for some of the largest municipalities and businesses in the U.S. and around the world, offering a wide range of cutting-edge and compliant security technologies, from AI-driven video analytics to fully integrated access control solutions. For more information visit www.vicon-security.com
AIS – Advanced Industrial Services, a subsidiary of Cemtrex, Inc., is a premier provider of industrial contracting services including millwrighting, rigging, piping, electrical, welding. AIS Installs high precision equipment in a wide variety of industrial markets including automotive, printing & graphics, industrial automation, packaging, and chemicals. AIS owns and operates a modern fleet of custom designed specialty equipment to assure safe and quick installation of your production equipment. Our talented staff participates in recurring instructional training, provided to ensure that the most current industry methods are being utilized to provide an efficient and safe working environment. For more information visit www.ais-york.com
For more information visit www.cemtrex.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the closing of the offering, gross proceeds from the offering, our new product offerings, expected use of proceeds, or any proposed fundraising activities. These forward-looking statements are based on management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward looking statements. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. These risks and uncertainties are discussed under the heading “Risk Factors” contained in our Form 10-K filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and we undertake no duty to update this information unless required by law.
https://www.globenewswire.com/newsroom/ti?nf=OTA1OTAyMiM2MTIzNTA1IzIwNDk3MDg=
https://ml.globenewswire.com/media/YmFhNDM0Y2ItNmNiNS00MmQ5LThkNDgtNGYyMDA2ZDBlNWU4LTEwNjEyNzk=/tiny/Cemtrex-Inc-.png
Investor Relations
Chris Tyson
Executive Vice President – MZ North America
Direct: 949-491-8235
CETX@mzgroup.us
www.mzgroup.us
Source: Cemtrex Inc.
Dickmo, nice work further confirming what IVDN management has been stating in its recent news and Twitter (X) postings. The new building codes taking effect across the US in 2024 are giving Insultex an even greater marketing advantage now. The IVDN product is ideally suited to the new continuous insulation requirement to achieve a higher standard of energy efficiency. These new standards will benefit homeowners with lower heating and cooling bills as well as the environment by reducing the demand on carbon producing energy suppliers to help resolve the climate change crisis. Its a win-win for all, including IVDN.
General Dynamics Board Increases Dividend
RESTON, Va., March 6, 2024 /PRNewswire/ -- The board of directors of General Dynamics (NYSE: GD) today declared a regular quarterly dividend of $1.42 per share on the company's common stock, payable May 10, 2024, to shareholders of record on April 12, 2024. This is the 27th consecutive annual dividend increase authorized by the General Dynamics board and represents a 7.6% increase over last year's dividend.
General Dynamics is a global aerospace and defense company that offers a broad portfolio of products and services in business aviation; ship construction and repair; land combat vehicles, weapons systems and munitions; and technology products and services. General Dynamics employs more than 100,000 people across 65 countries worldwide and generated $42.3 billion in revenue in 2023. More information about General Dynamics is available at http://www.gd.com.
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/general-dynamics-board-increases-dividend-302082058.html
$IVDN (16 million float): Superior Advancement for High Energy Efficiency Insulation Drawing Rising Interest and Commercial Demand; New International Patent Application Accepted to Maximize Marketing Potential
https://markets.financialcontent.com/startribune/article/getnews-2023-12-28-superior-advancement-for-high-energy-efficiency-insulation-drawing-rising-interest-and-commercial-demand-new-international-patent-application-accepted-to-maximize-marketing-potential-ivdn
From the article:
Very Small Stock Structure of Only 37 Million OS / 16 Million Float
- Sole Maker of Patented Insultex® Insulation Delivering Energy Saving Performance Far Superior to All Competition.
- Unique Evacuated Cell House Wrap Material Provides an Unmatched R-6 Rating Plus a Water Vapor, Air, and Wind Barrier and Other Superior Benefits.
- World International Patent Organization Application Accepted to Maximize Global Marketing Opportunities.
- "Leader in Green Assets" LIG Assets, Inc., in Association with Robert Plarr, Signs Sales and Licensing Agreement with IVDN.
- Insultex House Wrap® Already Being Installed by LIG Assets in Conjunction with Their Plans to Acquire Firm Doing $100-200 Million in Annualized Sales.
- Over a Dozen New Sales Accounts were Added in the Fiscal Fourth Quarter with Orders Being Fulfilled for Superior Insultex® House Wrap.
- New Building Codes Require Higher Insulation Performance and IVDN Meets or Exceeds These New Standards Where Many Competitors Do Not.
- Increased Order Fulfilment Capabilities Recently Added with Plans for Further Enhancement to Handle Increasing Customer Demand.
- New Sales Accounts Include Large-Scale Commercial Modular Construction Firm Guerdon, LLC.
- Greater Energy Savings from Insultex® Insulation Delivers Substantial Economic Gains and Tax Credits for the User and Also Carbon Reduction for the Environment.
- Insider Buying from Board Member with Lockheed Martin & NASA Background